Almirall returns InDex's ulcerative colitis drug
This article was originally published in Scrip
Executive Summary
Almirall has returned ulcerative colitis therapy Kappaproct to its originator company InDex Pharmaceuticals.
You may also be interested in...
InDex Gets Cash Boost For Phase III Ulcerative Colitis Drug
The Stockholm-based company is in a position to start the Phase III program for its ulcerative colitis candidate after raising over $64m in a rights issue.
InDex's Lead TLR9 Agonist Shows Promise In Ulcerative Colitis
A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.